Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial

1. François, B.
2. Lambden, S.
3. Fivez, T.
4. Gibot, S.
5. Derive, M.
6. Grouin, J.-M.
7. Salcedo-Magguilli, M.
8. Lemarié, J.
9. De Schryver, N.
10. Jalkanen, V.
11. Hicheur, T.
12. Garaud, J.-J.
13. Cuvier, V.
14. Ferrer, R.
15. Bestle, M.
16. Pettilä, V.
17. Mira, J.-P.
18. Bouisse, C.
19. Mercier, E.
20. Vermassen, J.
21. Huberlant, V.
22. Vinatier, I.
23. Anguel, N.
24. Levy, M.
25. Laterre, P.-F.
26. Asfar, P.
27. Nay, M.-A.
28. Guitton, C.
29. Quenot, J.-P.
30. Tran-Van, D.
31. Bohe, J.
32. Plantefève, G.
33. Nseir, S.
34. Lefrant, J.-Y.
35. Monnet, X.
36. Papazian, L.
37. Vinsonneau, C.
38. Constantin, J.-M.
39. Mebazaa, A.
40. Oueslati, H.
41. Escudero, D.
42. Martinez Sagasti, F.
43. Piacentini, E.
44. Ramirez Galleymore, P.
45. Dugernier, T.
46. Fagnoul, D.
47. Michaux, I.
48. Seibert, A.
49. Reinikainen, M.
50. Grøfte, T.
51. Martin-Loeches, I.
52. Laffey, J.
53. Mostrar todos los/as autores/as +